SCHEMBL862574

SCHEMBL862574

CS(=O)(=O)Nc1cccc(S(=O)(=O)NC(=O)c2c(-c3ccc[nH]c3=O)c3cc(Cl)ccc3n2Cc2ccccc2F)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C8 P10632 1/20 0.41
PTGDR2 Q9Y5Y4 1/20 0.37
KMT2A Q03164 4/20 0.37
PPARG P37231 5/20 0.37
MAPT P10636 3/20 0.36
MEN1 O00255 2/20 0.36
LMNA P02545 2/20 0.36
ALDH1A1 P00352 1/20 0.36
HPGD P15428 1/20 0.36
APOBEC3G Q9HC16 1/20 0.36
LOXL2 Q9Y4K0 2/20 0.35
ECE1 P42892 1/20 0.35
SERPINE1 P05121 1/20 0.34
PARG Q86W56 1/20 0.34
POLB P06746 1/20 0.34
NPY1R P25929 1/20 0.34
NPY2R P49146 1/20 0.34
TDP2 O95551 1/20 0.34
PDE4A P27815 1/20 0.34
PDE7A Q13946 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL862454 0.94 CYP2C8 (0.39) CYP2C8KMT2APPARGMAPTLOXL2
SCHEMBL862590 0.94 CYP2C8 (0.39) CYP2C8PTGDR2KMT2APPARGMAPT
SCHEMBL862901 0.93 CYP2C8 (0.39) CYP2C8PTGDR2KMT2APPARGMAPT
SCHEMBL862460 0.93 CYP2C8 (0.41) CYP2C8PTGDR2KMT2APPARGLOXL2
SCHEMBL862580 0.92 CYP2C8 (0.38) CYP2C8PTGDR2KMT2APPARGLOXL2
SCHEMBL862329 0.92 PPARG (0.40) CYP2C8KMT2APPARGLOXL2SERPINE1
SCHEMBL862708 0.92 CYP2C8 (0.38) CYP2C8KMT2APPARGMAPTMEN1
SCHEMBL832345 0.91 PPARG (0.40) PTGDR2KMT2APPARGMAPTMEN1
SCHEMBL862184 0.91 PPARG (0.39) CYP2C8KMT2APPARGMEN1LOXL2
SCHEMBL862296 0.91 PPARG (0.41) CYP2C8PTGDR2KMT2APPARGMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143305-B2 2,3-substituted indole derivatives for treating viral infections SCHERING CORPORATION (US) 2012-03-27 US disclosed
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS MERCK SHARP & DOHME CORP. 2011-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS IDO2, IDO1, IRF3 CYP2C8 847/4885PTGDR2 1609/4885KMT2A 321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.